Royalty Pharma plc (RPRX) concluded trading on Thursday at a closing price of $24.28, with 4.36 million shares of worth about $105.76 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -9.77% during that period and on December 19, 2024 the price saw a loss of about -0.78%. Currently the company’s common shares owned by public are about 446.04M shares, out of which, 380.55M shares are available for trading.
Stock saw a price change of -3.69% in past 5 days and over the past one month there was a price change of -6.65%. Year-to-date (YTD), RPRX shares are showing a performance of -13.56% which decreased to -12.60% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $24.46 but also hit the highest price of $31.66 during that period. The average intraday trading volume for Royalty Pharma plc shares is 2.60 million. The stock is currently trading -5.84% below its 20-day simple moving average (SMA20), while that difference is down -8.39% for SMA50 and it goes to -12.07% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Royalty Pharma plc (NASDAQ: RPRX) currently have 446.04M outstanding shares and institutions hold larger chunk of about 70.64% of that.
The stock has a current market capitalization of $14.31B and its 3Y-monthly beta is at 0.47. PE ratio of stock for trailing 12 months is 9.50, while it has posted earnings per share of $2.56 in the same period. It has Quick Ratio of 1.54 while making debt-to-equity ratio of 1.11. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RPRX, volatility over the week remained 2.22% while standing at 1.83% over the month.
Stock’s fiscal year EPS is expected to drop by -11.36% while it is estimated to increase by 10.36% in next year. EPS is likely to shrink at an annualized rate of -1.30% for next 5-years, compared to annual growth of 2.23% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by UBS on June 03, 2024 offering a Neutral rating for the stock and assigned a target price of $28 to it. Coverage by UBS stated Royalty Pharma plc (RPRX) stock as a Buy in their note to investors on June 14, 2022, suggesting a price target of $47 for the stock. On May 13, 2022, Scotiabank Initiated their recommendations, while on April 27, 2022, Goldman Initiated their ratings for the stock with a price target of $56. Stock get an Overweight rating from JP Morgan on April 14, 2022.
